(Q35042278)

English

A randomized, double-blind, placebo-controlled study to assess the efficacy and tolerability of gabapentin enacarbil in subjects with restless legs syndrome

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

A randomized, double-blind, placebo-controlled study to assess the efficacy and tolerability of gabapentin enacarbil in subjects with restless legs syndrome (English)

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

0 references

restless legs syndrome

0 references

0 references

gabapentin enacarbil

1 reference

ChEBI release 2020-05-28

author name string

Daniel O Lee

1

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

Ronald B Ziman

2

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

A Thomas Perkins

3

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

J Steven Poceta

4

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

Arthur S Walters

5

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

Ronald W Barrett

6

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

XP053 Study Group

7

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

language of work or name

0 references

publication date

1 June 2011

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

The Journal of Clinical Sleep Medicine

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

7

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

3

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

282-292

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

Pharmacokinetics and tolerability of single escalating doses of gabapentin enacarbil: a randomized-sequence, double-blind, placebo-controlled crossover study in healthy volunteers

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3113968

8 July 2018

A randomized, double-blind, placebo-controlled, crossover study of XP13512/GSK1838262 in the treatment of patients with primary restless legs syndrome

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3113968

8 July 2018

Effect of pramipexole on RLS symptoms and sleep: a randomized, double-blind, placebo-controlled trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3113968

8 July 2018

Clinical pharmacokinetics of XP13512, a novel transported prodrug of gabapentin

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3113968

8 July 2018

Restless legs syndrome prevalence and impact: REST general population study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3113968

8 July 2018

XP13512 [(+/-)-1-([(alpha-isobutanoyloxyethoxy)carbonyl] aminomethyl)-1-cyclohexane acetic acid], a novel gabapentin prodrug: II. Improved oral bioavailability, dose proportionality, and colonic absorption compared with gabapentin in rats and monkey

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3113968

8 July 2018

XP13512 [(+/-)-1-([(alpha-isobutanoyloxyethoxy)carbonyl] aminomethyl)-1-cyclohexane acetic acid], a novel gabapentin prodrug: I. Design, synthesis, enzymatic conversion to gabapentin, and transport by intestinal solute transporters

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3113968

8 July 2018

Ropinirole in the treatment of restless legs syndrome: results from the TREAT RLS 1 study, a 12 week, randomised, placebo controlled study in 10 European countries

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3113968

8 July 2018

Validation of the International Restless Legs Syndrome Study Group rating scale for restless legs syndrome

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3113968

8 July 2018

Restless legs syndrome: diagnostic criteria, special considerations, and epidemiology. A report from the restless legs syndrome diagnosis and epidemiology workshop at the National Institutes of Health

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3113968

8 July 2018

Gabapentin versus Ropinirole in the Treatment of Idiopathic Restless Legs Syndrome

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3113968

8 July 2018

Treatment of idiopathic restless legs syndrome (RLS) with gabapentin

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3113968

8 July 2018

Pharmacokinetics and metabolism of gabapentin in rat, dog and man.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3113968

8 July 2018

A New Method for Measuring Daytime Sleepiness: The Epworth Sleepiness Scale

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3113968

8 July 2018

Gabapentin enacarbil in restless legs syndrome: a phase 2b, 2-week, randomized, double-blind, placebo-controlled trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3113968

25 October 2018

Randomized, double-blind, placebo-controlled study of XP13512/GSK1838262 in patients with RLS.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3113968

25 October 2018

Psychometric evaluation and tests of validity of the Medical Outcomes Study 12-item Sleep Scale (MOS sleep).

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3113968

25 October 2018

A better future for patients with restless legs syndrome.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3113968

25 October 2018

Efficacy and safety of pramipexole in restless legs syndrome.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3113968

25 October 2018

Ropinirole in the treatment of patients with restless legs syndrome: a US-based randomized, double-blind, placebo-controlled clinical trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3113968

25 October 2018

Ropinirole is effective in the treatment of restless legs syndrome. TREAT RLS 2: a 12-week, double-blind, randomized, parallel-group, placebo-controlled study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3113968

25 October 2018

Long-term treatment of restless legs syndrome with dopamine agonists

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3113968

25 October 2018

Modeling the causal relationships between symptoms associated with restless legs syndrome and the patient-reported impact of RLS.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3113968

25 October 2018

Impact, diagnosis and treatment of restless legs syndrome (RLS) in a primary care population: the REST (RLS epidemiology, symptoms, and treatment) primary care study.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3113968

25 October 2018

Augmentation and tolerance with long-term pramipexole treatment of restless legs syndrome (RLS).

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3113968

25 October 2018

Treatment of restless legs syndrome with gabapentin: a double-blind, cross-over study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3113968

25 October 2018

Test-retest reliability and validity of the Pittsburgh Sleep Quality Index in primary insomnia.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3113968

25 October 2018

The Pittsburgh Sleep Diary.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3113968

25 October 2018

World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3113968

9 December 2018

A saturable transport mechanism in the intestinal absorption of gabapentin is the underlying cause of the lack of proportionality between increasing dose and drug levels in plasma

1 reference

https://pubmed.ncbi.nlm.nih.gov/21677899

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Inter- and intra-subject variability in gabapentin absorption and absolute bioavailability

1 reference

https://pubmed.ncbi.nlm.nih.gov/21677899

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Failure of Absorption of Gabapentin After Rectal Administration

1 reference

https://pubmed.ncbi.nlm.nih.gov/21677899

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Gabapentin bioavailability: effect of dose and frequency of administration in adult patients with epilepsy

1 reference

https://pubmed.ncbi.nlm.nih.gov/21677899

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.5664/JCSM.1074

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

PMC publication ID

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q35042278&oldid=2087477109"